MK-6482 is an experimental anti-cancer treatment that works by inhibiting a molecule called HIF-2-alpha. This inhibition prevents cancerous cells from obtaining the oxygen they need to grow and divide.
Since this drug is still in the clinical trial phase, it has the placeholder name MK-6482 rather than a commercial trade name.
In the trial, the experimental drug will be tested against an already approved anti-cancer therapy called Everolimus (Afinitor®). Everolimus causes inhibition of the mTOR molecule and works to deprive tumours of the nutrients they need to survive.
This study will have two treatment groups that will be randomly assigned upon your enrollment in the trial:
Group 1: Experimental therapy: – MK-6482
Group 2: Standard of care therapy -Everolimus
In order to maximize effectiveness and minimize side effects, different doses of each drug may be used to determine the optimal dosage of these medications.
There is no control group in the study, so there will be no “placebo”, and all patients will receive some form of treatment.
- Clear cell kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- Must have received prior therapy with both immunotherapy (e.g. Nivolumab) and a TKI (e.g. sunitinib)
- Must not have received more than 3 prior treatments
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBC Cancer - Vancouver Centre||Principal InvestigatorDr. Christian Kollmannsberger||LocationVancouver, BC||Trial StatusRecruiting|
|Hospital / Cancer CentreCHU de Quebec-Universite Laval-Hotel Dieu de Quebec||Principal InvestigatorNot Given||LocationQuébec, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreCentre Hospitalier de l'Universite de Montreal - CHUM||Principal InvestigatorNot Given||LocationMontreal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal InvestigatorNot Given||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreSunnybrook Research Institute||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreNova Scotia Health Authority QEII-HSC||Principal InvestigatorNot Given||LocationHalifax, NS||Trial StatusRecruiting|